Showing results (101-110 of 127) with videos related to
Sort By:
Pageof 13
Cancer Discovery|July 31, 2025
Sucralose consumption ablates cancer immunotherapy response through microbiome disruptionKristin M Morder, Madison Nguyen, Drew N Wilfahrt, et al.Brain Communications|November 3, 2021
High-throughput imaging of ATG9A distribution as a diagnostic functional assay for adaptor protein complex 4-associated hereditary spastic paraplegiaDarius Ebrahimi-Fakhari, Julian E Alecu, Barbara Brechmann, et al.Frontiers in Immunology|July 12, 2023
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomesLilit Karapetyan, Hassan M AbuShukair, Aofei Li, et al.Journal for Immunotherapy of Cancer|February 12, 2025
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanomaAlexandra G Tompkins, Zane N Gray, Rebekah E Dadey, et al.Journal for Immunotherapy of Cancer|May 15, 2026
Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanomaJii Bum Lee, Sujeong Baek, Dong Kwon Kim, et al.Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.Pageof 13